ATAI Life Sciences BV (ATAI) - Net Assets
Based on the latest financial reports, ATAI Life Sciences BV (ATAI) has net assets worth $198.78 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($264.88 Million) and total liabilities ($66.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ATAI intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $198.78 Million |
| % of Total Assets | 75.05% |
| Annual Growth Rate | 24.44% |
| 5-Year Change | -42.48% |
| 10-Year Change | N/A |
| Growth Volatility | 119.97 |
ATAI Life Sciences BV - Net Assets Trend (2019–2025)
This chart illustrates how ATAI Life Sciences BV's net assets have evolved over time, based on quarterly financial data. See ATAI defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for ATAI Life Sciences BV (2019–2025)
The table below shows the annual net assets of ATAI Life Sciences BV from 2019 to 2025. For live valuation and market cap data, see market cap of ATAI Life Sciences BV.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $222.00 Million | +90.47% |
| 2024-12-31 | $116.55 Million | -52.29% |
| 2023-12-31 | $244.32 Million | -8.07% |
| 2022-12-31 | $265.77 Million | -31.14% |
| 2021-12-31 | $385.96 Million | +304.70% |
| 2020-12-31 | $95.37 Million | +59.53% |
| 2019-12-31 | $59.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ATAI Life Sciences BV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 134079200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.63 Million | 1.64% |
| Other Comprehensive Income | $-20.93 Million | -9.43% |
| Other Components | $1.60 Billion | 720.87% |
| Total Equity | $221.87 Million | 100.00% |
ATAI Life Sciences BV Competitors by Market Cap
The table below lists competitors of ATAI Life Sciences BV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong Yizumi Precision Machinery Co Ltd
SHE:300415
|
$1.45 Billion |
|
Ufuk Yatirim Yonetim Ve Gayrimenkul AS
IS:UFUK
|
$1.45 Billion |
|
Tangshan Jidong Cement Co Ltd
SHE:000401
|
$1.45 Billion |
|
Bilia AB (publ)
ST:BILI-A
|
$1.46 Billion |
|
Paradox Interactive AB (publ)
ST:PDX
|
$1.45 Billion |
|
Hotel Shilla
KO:008770
|
$1.45 Billion |
|
Youngone Holdi
KO:009970
|
$1.45 Billion |
|
Telecom Argentina SA ADR
NYSE:TEO
|
$1.45 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ATAI Life Sciences BV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 116,297,000 to 221,874,000, a change of 105,577,000 (90.8%).
- Net loss of 660,047,000 reduced equity.
- Share repurchases of 6,635,000 reduced equity.
- New share issuances of 258,128,000 increased equity.
- Other comprehensive income decreased equity by 2,460,000.
- Other factors increased equity by 516,591,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-660.05 Million | -297.49% |
| Share Repurchases | $6.63 Million | -2.99% |
| Share Issuances | $258.13 Million | +116.34% |
| Other Comprehensive Income | $-2.46 Million | -1.11% |
| Other Changes | $516.59 Million | +232.83% |
| Total Change | $- | 90.78% |
Book Value vs Market Value Analysis
This analysis compares ATAI Life Sciences BV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.57x to 4.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.39 | $4.07 | x |
| 2020-12-31 | $0.60 | $4.07 | x |
| 2021-12-31 | $2.35 | $4.07 | x |
| 2022-12-31 | $1.67 | $4.07 | x |
| 2023-12-31 | $1.53 | $4.07 | x |
| 2024-12-31 | $0.73 | $4.07 | x |
| 2025-12-31 | $0.98 | $4.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ATAI Life Sciences BV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -297.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16142.02%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.40x
- Recent ROE (-297.49%) is below the historical average (-108.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -24.06% | 0.00% | 0.00x | 1.06x | $-20.01 Million |
| 2020 | -187.01% | -854.34% | 0.18x | 1.23x | $-178.93 Million |
| 2021 | -44.52% | -823.56% | 0.05x | 1.10x | $-205.50 Million |
| 2022 | -58.44% | -65401.29% | 0.00x | 1.17x | $-178.46 Million |
| 2023 | -16.56% | -12810.19% | 0.00x | 1.21x | $-64.52 Million |
| 2024 | -128.35% | -48463.96% | 0.00x | 1.37x | $-160.90 Million |
| 2025 | -297.49% | -16142.02% | 0.01x | 1.40x | $-682.23 Million |
Industry Comparison
This section compares ATAI Life Sciences BV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ATAI Life Sciences BV (ATAI) | $198.78 Million | -24.06% | 0.33x | $1.45 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About ATAI Life Sciences BV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more